140 related articles for article (PubMed ID: 10572607)
1. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Cerny T; Leyvraz S; von Briel T; Küpfer A; Schaad R; Schmitz SF; Honegger P; Sessa C; Brunner J; Boddy AV
Ann Oncol; 1999 Sep; 10(9):1087-94. PubMed ID: 10572607
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
[TBL] [Abstract][Full Text] [Related]
3. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
[TBL] [Abstract][Full Text] [Related]
4. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
5. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
[TBL] [Abstract][Full Text] [Related]
7. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
9. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Chugh R; Wagner T; Griffith KA; Taylor JM; Thomas DG; Worden FP; Leu KM; Zalupski MM; Baker LH
Cancer; 2007 Jun; 109(11):2315-22. PubMed ID: 17464949
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
Buesa JM; López-Pousa A; Martín J; Antón A; García del Muro J; Bellmunt J; Arranz F; Valentí V; Escudero P; Menéndez D; Casado A; Poveda A
Ann Oncol; 1998 Aug; 9(8):871-6. PubMed ID: 9789610
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
[TBL] [Abstract][Full Text] [Related]
12. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
13. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
14. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
15. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
[TBL] [Abstract][Full Text] [Related]
16. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors.
Frustaci S; Buonadonna A; Romanini A; Comandone A; Dalla Palma M; Gamucci T; Verusio C; Lionetto R; Dani C; Casali P; Santoro A
Tumori; 1999; 85(4):229-33. PubMed ID: 10587022
[TBL] [Abstract][Full Text] [Related]
17. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.
Frustaci S; Buonadonna A; Galligioni E; Favaro D; De Paoli A; Lo Re G; Sorio R; Tumolo S; Monfardini S
J Clin Oncol; 1997 Apr; 15(4):1418-26. PubMed ID: 9193334
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
[TBL] [Abstract][Full Text] [Related]
19. 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
Brain EC; Mita A; Soulié P; Errihani H; Hardy Bessard AC; Chaouche M; Alexandre J; Delord JP; Cvitkovic E; Jasmin C; Misset JL
J Cancer Res Clin Oncol; 1997; 123(4):227-31. PubMed ID: 9177496
[TBL] [Abstract][Full Text] [Related]
20. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
